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ABSTRACT
Objective: This study sought to determine the correlation between trough plasma amikacin concentrations and urinary normalized kidney injury 
molecule-1 (KIM-1) concentrations as an early biomarker of nephrotoxicity in patients with sepsis who are hospitalized in an intensive care unit.
Methods: In this pilot study, 12 patients with sepsis were treated with amikacin 1000 mg/day between May 2015 and September 2015. The correlation 
between trough plasma amikacin concentrations measured after the third dose and the elevation of urinary normalized KIM-1 concentrations after 
the third amikacin dose relative to the first/second dose was evaluated.
Results: In total, three patients had trough plasma amikacin concentrations exceeding the safe level (>10 µg/ml). Furthermore, eight patients 
displayed higher normalized KIM-1 concentrations after third dose than after the first/second dose; however, there was no correlation between 
trough amikacin concentrations and the elevation of urinary normalized KIM-1 concentrations (r=0.3, p=0.3).
Conclusion: The study results illustrated that short-term treatment with an amikacin dose of 1000 mg/day was generally safe in patients with sepsis.
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INTRODUCTION
Sepsis is a common cause of mortality, and severe sepsis results in death 
in up to 50% of patients [1]. Aminoglycosides, especially amikacin, are 
the most commonly used antibiotics in patients with sepsis due to 
Gram-negative bacterial infections even though these drugs can induce 
nephrotoxicity in 10–20% of patients [2].
Amikacin has a different structure than other aminoglycosides; 
therefore, it is not inactivated by enzymes that commonly inactivate 
gentamicin [2]. An adequate plasma level of amikacin is needed to kill 
the bacteria that cause sepsis. The target amikacin concentration for 
treating bacterial sepsis is 20–40 µg/ml, whereas the trough level to 
avoid nephrotoxicity is less than 10 µg/ml [3,4].
Acute kidney injury (AKI) is traditionally diagnosed by measuring blood 
urea nitrogen and serum creatinine levels; however, these parameters are 
neither sensitive nor specific for establishing a diagnosis of AKI. A more 
specific AKI biomarker is kidney injury molecule-1 (KIM-1) [5]. KIM-1 is a 
tubular protein that is induced by ischemic reperfusion injury or exposure 
to proximal tubule toxins. KIM-1 can be produced at the site of injury, and 
it can be measured quantitatively, rapidly, and easily in urine or blood [6].
Currently, the dose of amikacin used in the intensive care unit (ICU) of 
Cipto Mangunkusumo Hospital (RSCM) is 1000 mg/day, compared to 
a recommended dose of 15 mg/kg BW [7,8]. It is unknown whether the 
currently used dose would generate a trough amikacin level exceeding the 
minimum level known to cause nephrotoxicity. This study examined trough 
plasma amikacin levels in patients with sepsis hospitalized in the ICU of 
RSCM who were treated with amikacin 1000 mg/day, and the relationship 
between trough amikacin and urinary KIM-1 levels was analyzed.
METHODS
Trough plasma amikacin levels and urinary normalized KIM-1 
levels were measured in patients with sepsis who received amikacin 
1000 mg/day in the ICU of RSCM. All patients in this study had good 
renal function. Trough plasma amikacin levels were measured after 
the third dose (immediately before the fourth dose was administered), 
whereas urinary normalized KIM-1 levels were measured after the 
first/second and third doses. The correlations of the difference of 
normalized KIM-1 levels between the first/second and third doses and 
the third-dose trough amikacin levels were evaluated.
Blood samples were obtained from patients 5 min before the fourth 
dose of amikacin was administered to measure trough amikacin levels. 
Plasma samples were transferred to the pharmacokinetics laboratory 
after centrifugation and stored at −20°C before analysis. Plasma 
amikacin levels were measured through liquid chromatography-tandem 
mass spectrometry using a Waters Alliance 2695 high-performance 
liquid chromatography system and Quatro Micro Triple Quadrupole MS 
detector with the lowest limit of quantification of 1 µg/ml. To measure 
absolute urinary KIM-1 levels, 1 ml of a 24-h urine sample (starting 
immediately after administration of the first or second dose of amikacin 
until immediately before the next dose) was used. The urinary samples 
were analyzed through enzyme-linked immunosorbent assay using a 
KIM-1 kit (R and D Systems DKM 100). The remainder of the urinary 
samples was transported to the clinical pathology laboratory of RSCM 
to quantify urine creatinine levels.
The correlation between trough plasma amikacin levels and the 
increase of normalized KIM-1 levels was verified using Spearman’s test. 
The differences between the first-/second-dose and third-dose urinary 
normalized KIM-1 levels were analyzed using Wilcoxon’s test.
RESULTS
Subject selection was performed from May 2015 to September 2015. 
Among 20 targeted patients, only 15 could be recruited. Of these subjects, 
one died before the sample for trough amikacin and third-dose KIM-1 
level measurements were obtained. A second subject could not provide 
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the day 3 urinary creatinine measurement sample. Another subject was 
excluded due to prior continuous renal replacement therapy. Thus, data 
were analyzed for 12 subjects. The basic characteristics of the subjects 
are shown in Table 1.
The administration of amikacin 1000 mg/day resulted in varied trough 
amikacin levels after the third dose (Table 2). In total, three subjects 
had trough levels exceeding 10 µg/ml.
In this study, 8/12 subjects (66.7%) exhibited elevated normalized 
urinary KIM-1 levels after the third dose compared to those after the 
first or second dose.
The Spearman correlation test revealed no correlation between 
trough amikacin levels and changes of urinary KIM-1 levels among the 
12 subjects (r=0.3, p=0.3). Meanwhile, patient 7 was excluded from 
Pearson’s correlation test because this patient’s trough amikacin level 
differed by >2 standard deviation from the median trough level of the 
subjects. However, the result also revealed no correlation between 
Eight subjects in this study exhibited higher 3rd-day normalized KIM-1 
levels compared to the 1st/2nd-day levels; however, the increase was not 
statistically significant (Wilcoxon’s test, p=0.19, Table 3). Varied urinary 
KIM-1 levels were also detected among the subjects (Tables 3 and 4).
DISCUSSION
This study evaluated the correlation between the trough level of 
amikacin following administration at 1000 mg/day and the increase of 
normalized KIM-1 levels as a marker of kidney damage in patients with 
sepsis. The failure to obtain a correlation between the variables could 
be due to the lower-than-expected number of enrolled subjects. This 
may have reduced the power of the statistical test.
Despite the subjects ranging in weight from 35 to 70 kg, the dose of 
amikacin is 1000 mg/day for all patients with sepsis in the ICU of RSCM 
regardless of their weight. Consequently, the trough amikacin level 
in patient 7, who had the lowest weight, exceeded the recommended 
level of 15–25 mg/kg [7,8]. This patient received an amikacin dose of 
28.6 mg/kg BW, leading to elevated trough amikacin and normalized 
KIM-1 levels. Based on these findings, this patient may have had an 
increased risk of developing nephrotoxicity [9].
Conversely, patient 12 (90 kg), who had a body mass index (BMI) of 
37, exhibited increased normalized KIM-1 levels after the third dose 
despite a trough amikacin level below the safe threshold. Determination 
of amikacin dose for obese patients is based on the ideal body weight 
rather than the actual body weight, using the formula: ideal body 
weight + 0.4 (total body weight- ideal body weight)×amikacin dose [10]. 
The elevation of KIM-1 levels may be related to the condition of the 
patient, who had septic shock. In line with these data, a study by Balqis 
et al. [11] found that patients with sepsis and AKI have higher absolute 
KIM-1 levels (median=2.7 ng/ml, range=0.7–13.4) than those without 
AKI (median=0.8 ng/ml, range=0–3.4, p<0.001).
This study had a number of limitations. First, the number of subjects 
was small and fewer than expected. The sample size required according 
to the obtained correlation value (r) in this study, as determined using 
the formula {(Zα+Zβ)/(0.5ln[1+r]/[1−r])}2+3 [14], was 51.
Table 1: Basic characteristics of the subjects










Table 2: Trough level plasma of amikacin
No Patient Cmin (µg/ml)
1 Patient 1 1.26
2 Patient 2 4.56
3 Patient 4 6.74
4 Patient 5 4.83
5 Patient 6 3.19
6 Patient 7 27.04
7 Patient 9 3.24
8 Patient 10 12.59
9 Patient 11 8.29
10 Patient 12 8.04
11 Patient 13 13.75
12 Patient 15 4.22
Median=5.78
Table 3: KIM‑1 levels in urine
No Subject Absolute KIM‑1 level 
after the 1st or 2nd 
dose (ng/ml)
Absolute KIM‑1 level 
after the 3rd dose  
(ng/ml)
Normalized KIM‑1 
level after the 1st or 2nd 
dose (µg/g)
Normalized KIM‑1 
level after the 3rd 
dose (µg/g)
Difference between the 
1st or 2nd dose and 3rd 
dose (µg/g)*
1 Patient 1 1.78 0.45 1.37 0.68 −0.69
2 Patient 2 1.31 1.60 1.74 3.09 1.35
3 Patient 4 0.23 0.04 0.39 0.20 −0.19
4 Patient 5 0.53 0.41 1.06 1.25 0.19
5 Patient 6 0.67 0.54 1.42 1.30 −0.12
6 Patient 7 0.95 1.01 2.97 3.68 0.71
7 Patient 9 0.80 1.48 4.74 6.22 1.48
8 Patient 10 2.08 3.98 5.81 9.31 3.5
9 Patient 11 5.49 3.96 23.13 18.68 −4.45
10 Patient 12 8.56 6.15 25.22 27.72 2.5
11 Patient 13 1.87 0.79 4.68 5.48 0.8
12 Patient 15 9.45 6.80 17.02 17.10 0.08
*The third-dose normalized KIM-1 level was subtracted from first- or second-dose normalized KIM-1 level, KIM-1: Kidney injury molecule-1
urinary  normalized  KIM-1  levels  between  the  third  and 
first/second doses (p=0.478; r=0.24).
trough amikacin levels after the third dose and the difference of the 
Meanwhile, patient 10 had an increased normalized KIM-1 level after
 the third dose. This patient, who was 60 years old, had a 
history  of  AKI  that  was  resolved  2  week  before  sepsis 
developed.  The  risk  factors  for  aminoglycoside-induced 
nephrotoxicity  include  age,  concurrent  disease,  hepatic 
dysfunction, septic condition, and kidney dysfunction [12]. However, 
a  study performed by Boghdady et  al.  [13] identified no association 
of KIM-1 levels with age, sex, and BMI in 79 critically ill patients.
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Another limitation was that the initial KIM-1 level before amikacin 
administration was not measured due to difficulties in finding 
eligible patients for this study. The initial level was needed to obtain 
information about the kidney function of the patients before therapy 
and ensure the absence of other factors affecting nephrotoxicity risk. 
In addition, KIM-1 levels were not compared between the patients and 
healthy controls.
CONCLUSION
In this study, no correlation was found between the trough amikacin 
levels and the elevation of urinary normalized KIM-1 levels after the 
third amikacin dose. After 3 days of treatment with 1000 mg/day 
amikacin, the trough levels of the drug in patients with sepsis were 
generally within the safe limits for avoiding nephrotoxicity (<10 µg/ml).
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